Home Neoplasma 2018 Neoplasma Vol.65, No.3, p.398-405, 2018

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.3, p.398-405, 2018

Title: Evaluation of overall survival rate of different therapies in the treatment of T1–T3 prostate cancer: a network meta-analysis
Author: S. Y. CHEN, Y. DU, Q. SHAO, J. S. LI, H. Y. CHEN

Abstract: We performed this network meta-analysis (NMA) in order to compare the overall survival rate of six different therapies of T1–T3 prostate cancer (PC). The therapies include radiotherapy (RT), endocrine therapy (ET), Cryoablation (CRYO), radical prostatectomy (RP), RT+ET and RP+ET. Pubmed, Embase, Cochrane Library, Google Scholar, Web of Science and MEDLINE were searched to collect relevant literature from the inception of the study till February 2017. Cohort studies meeting the inclusion criteria were included in the study. A combination of direct and indirect evidence was performed to evaluate the odds ratio (OR) and draw surface under the cumulative ranking curves (SUCRA). Nine eligible cohort studies were included in this NMA, including 20,644 patients suffering from T1–T3 PC. The pairwise meta-analysis revealed   that compared with the ET regimen, the RP and RP+ET regimens exhibited comparatively higher overall survival rates (OR=2.81, 95% CI=2.09~3.78; OR=3.15, 95% CI=1.80~5.50, respectively). The results of SUCRA values demonstrated that the RP + ET regimen occupied the first place (89.5%) in terms of overall survival rate, and the RP regimen came second (84.83%). Thus, the RP+ET regimen had better efficacy in the treatment of T1–T3 PC in combined-therapeutic regimens, and the RP regimen presented better efficacy in mono-therapeutic regimen. Our findings indicate that the RP+ET regimen had better efficacy on improving the overall survival rate of T1–T3 PC patients, and the RP regimen ranked second.

Keywords: prostate cancer, therapies, overall survival rate, cohort studies, Bayesian network model, surface under the cumulative ranking curves (SUCRA)
Published online: 16-May-2018
Year: 2018, Volume: 65, Issue: 3 Page From: 398, Page To: 405
doi:10.4149/neo_2018_170419N288
Price: 19.20 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.